GIGA-CARBON-NEUTRALITY
11.11.2021 09:54:11 CET | Business Wire | Press release
Giga Carbon Neutrality (GCN), the clean trucking and technology company, today unveiled a comprehensive range of zero-emission commercial vehicles that it plans to bring to market over the next two years – answering the call from the world’s transportation and logistics operators for a fleet of different options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005555/en/
GCN will launch 21 different battery-electric and hydrogen fuel-cell powered vehicles by the end of 2023. GCN’s portfolio is configurable to a wide range of commercial use cases and includes a tractor unit, buses and last-mile logistics vehicles. The company’s first prototype hydrogen-fueled tractor unit is currently undergoing advanced road and usability trials in China.
GCN designs its vehicles at a state-of-the-art research and development centre located in Hangzhou , China. GCN has developed its own proprietary hydrogen fuel-cell technology and will source batteries from leading manufacturers initially.
The GCN vehicles are manufactured using lightweight stainless steel and composite materials to improve safety and deliver reductions in weight and energy consumption of at least 10 per cent. The bodies of GCN vehicles are designed to last for 20 years, significantly longer than vehicles from other providers on the market.
GCN is working with public and private sector partners to provide clean energy storage, charging and refueling infrastructure, as well as specialist financing to support the adoption of its zero-emission commercial vehicles globally.
Marty Wade, CEO at Giga Carbon Neutrality, comments: “We are thrilled to give the world its first look at the future of zero-emission commercial transportation.”
“GCN is enabling a carbon-neutral future for some of the world’s most energy-intensive industries, with clean energy vehicles, new technologies and a fueling ecosystem to make running clean, reliable vehicle fleets easy for commercial transportation companies.”
Giga’s initial fleet of zero-emission commercial vehicles
Several GCN vehicles are available to order immediately, with delivery times of between three and 12 months. The company’s initial range includes:
- The GCN Hydrogen Tractor: A 44-tonne hydrogen fuel-cell truck with a top speed of 90 kph and 580 km range before refueling. Streamlined to minimise wind-resistance, GCN’s ‘heavy truck’ features an ergonomic cab design and a range of intelligent safety systems such as driver fatigue warning systems as standard. A prototype of this vehicle is already on the road in China.
- The GCN City Bus: A 12-metre transit bus for urban public transport. Capable of carrying up to 95 passengers, GCN’s city bus has a 350 km range on a battery-electric power train and features a monocoque body and collision protection structure offering improved safety for the driver and passengers. This vehicle is designed to meet European Union approved standards for use in its 27 member states.
- The GCN Pure Electric Minibus: A 6.9-metre battery-electric minibus with an ultra-long wheelbase and flat floor structure to provide capacity for up to 13 passengers. GCN’s minibuses have a 240 km range on a single charge and are already being used on the road in Hong Kong. Autonomous vehicles can also be developed based on this platform.
- The GCN Electric Logistics Vehicle: An 8-tonne battery-electric truck to support last-mile logistics in urban and rural areas. GCN’s logistics truck has a spacious loading area, can be configured to customer needs and can cover 250 km on a single charge.
About Giga Carbon Neutrality (www.gigacarbonneutrality.com )
Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
